Ototoxicity Associated with Oxaliplatin in a Patient with Pancreatic Cancer

  • Sun Young Oh Department of Hematology/Oncology and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA
  • Nawal Wasif Brookline High School. Brookline, MA, USA
  • Marie Carmel Garcon Columbia University Medical Center. New York, NY, USA
  • Gladys Rodriguez Columbia University Medical Center. New York, NY, USA
  • Muhammad Wasif Saif Department of Hematology/Oncology and Experimental Therapeutics, Tufts University School of Medicine. Boston, MA, USA
Keywords: Deafness, Hearing Loss, oxaliplatin, Pancreatic Neoplasms, Peripheral Nervous System Diseases


Context Oxaliplatin, a third-generation platinum derivative is commonly used for the treatment of colorectal cancer, pancreatic cancer, upper gastrointestinal cancer, hepatobiliary cancer, and ovarian cancer. Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients. Case report We present a case of a female patient with locally advanced unresectable pancreatic cancer who developed hearing loss after receiving oxaliplatin and gemcitabine. The dose of oxaliplatin was reduced but continued due to clinical benefit and radiological response. Discussion To the best of our knowledge, this is the third case report of oxaliplatin-induced ototoxicity. Ototoxicity seems to be a rare complication of oxaliplatin therapy. Regardless of its rare occurrence, clinicians should be aware of this severe complication and be diligent in monitoring patients’s clinical symptoms.

Image: Post-oxaliplatin audiogram.


Download data is not yet available.


Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9(1):8-12.

Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC. Literature review and practical aspects on the management of oxaliplatin-associated toxicity Clin Colorectal Cancer. 2012 Jun;11(2):93-100

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25

Li J, Merl M, Lee MX, Kaley K, Saif MW. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opin Drug Saf. 2010 Mar;9(2):207-13.

Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, Paitel JF, Mineur L, Artru P, André T, Louvet C. First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. Bull Cancer. 2009 May;96(5):E18-22.

Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag. 2005 Dec;1(4):249-58.

Saif MW. Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy. J Appl Res. 2004 Jan 1;4(4):576-582.

Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007 Nov;8(16):2719-27.

Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arnér ES, Shoshan M, Ehrsson H, Laurell G. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst. 2009 Jan 7;101(1):37-47

Ding D, Allman BL, Salvi R. Review: ototoxic characteristics of platinum antitumor drugs . Anat Rec (Hoboken). 2012 Nov;295(11):1851-67

Malhotra NK, Aslam R, Lipman SP, Bilski VJ. Acute ototoxicity from a single infusion of oxaliplatin. Ear Nose Throat J. 2010 Jun;89(6):258-61

Vietor NO, George BJ. Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract. 2012 Sep;18(3):355-9.

Cassidy J, Misset JL Oxaliplatin-related side effects:characteristics and management. Semin Oncol. 2002 Oct;29(5 Suppl 15):11-20.

Post-oxaliplatin audiogram
How to Cite
OhS., WasifN., GarconM., RodriguezG., & SaifM. (2013). Ototoxicity Associated with Oxaliplatin in a Patient with Pancreatic Cancer. JOP. Journal of the Pancreas, 14(6), 676-679. https://doi.org/10.6092/1590-8577/1629